Odonate Therapeutics is a pharmaceutical company focused on the development of therapeutics for patients with cancer. Co.'s initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. Tesetaxel has several pharmacologic properties, including: oral administration with a low pill burden; a long terminal plasma half-life in humans, enabling the maintenance of adequate drug levels with relatively infrequent dosing; no history of hypersensitivity (allergic) reactions; and activity against chemotherapy-resistant tumors. The ODT average annual return since 2017 is shown above.
The Average Annual Return on the ODT average annual return since 2017 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ODT average annual return since 2017 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ODT average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|